Aims: The CardioPulmonary resuscitation with Argon (CPAr) trial evaluates the clinical neuroprotective efficacy and safety of post-resuscitation ventilation with a 70/30 argon/oxygen (Ar/O2) gas mixture compared to standard care ventilation with 30% O2 in unconscious adults resuscitated from out-of-hospital cardiac arrest (OHCA). Methods: CPAr is an allocation-concealed, single-blinded, multi-centre, phase II, pre-marketing, randomised controlled trial (RCT). The study aims to recruit 120 patients across tertiary intensive care units (ICUs) in Italy. Eligible participants are unconscious adult OHCA survivors with a shockable presenting rhythm. Upon ICU admission, patients are individually randomised in a 1:1 ratio to receive either 4-h ventilation with 70/30 Ar/O2 via an experimental ventilator, or standard ICU ventilation with 30% O2. All patients receive guideline-based post-resuscitation care. Inclusion is conducted under a deferred consent model, with consent obtained from patients or legal representatives once clinically appropriate. The primary clinical efficacy outcome is serum neuron-specific enolase (NSE) concentration at 48 h, as a surrogate marker of neurological injury. Secondary outcomes include markers of myocardial and multiorgan injury, neuroimaging signs of brain injury, survival, and neurological recovery (Cerebral Performance Category, CPC) up to 6 months. Safety outcomes include the incidence, timing, and duration of O2 desaturation requiring discontinuation of Ar, and haemodynamic adverse events. Patients are followed up to 6 months, with outcome assessment at ICU/hospital discharge, 1-and 6-months post-CA. A centralized plasma and serum biobank will support future mechanistic analyses. Conclusion: CPAr trial is the first RCT to assess the efficacy and safety of Ar ventilation in humans following OHCA and may inform future neuroprotective strategies in post-resuscitation care. Trial registration: EudraCT-No.: 2018-003047-32; CTIS code: 2024-516864-27-00; ClinicalTrials.gov identifier: NCT05482945.
CardioPulmonary resuscitation with Argon (CPAr): A protocol for a randomised controlled multicentre clinical trial
Pozzi M.;Robba C.;Semeraro F.;Fumagalli R.;Giussani G.;Castaldi S.;Rosati A.;Patroniti N.;Battaglini D.;Balzani E.;
2025-01-01
Abstract
Aims: The CardioPulmonary resuscitation with Argon (CPAr) trial evaluates the clinical neuroprotective efficacy and safety of post-resuscitation ventilation with a 70/30 argon/oxygen (Ar/O2) gas mixture compared to standard care ventilation with 30% O2 in unconscious adults resuscitated from out-of-hospital cardiac arrest (OHCA). Methods: CPAr is an allocation-concealed, single-blinded, multi-centre, phase II, pre-marketing, randomised controlled trial (RCT). The study aims to recruit 120 patients across tertiary intensive care units (ICUs) in Italy. Eligible participants are unconscious adult OHCA survivors with a shockable presenting rhythm. Upon ICU admission, patients are individually randomised in a 1:1 ratio to receive either 4-h ventilation with 70/30 Ar/O2 via an experimental ventilator, or standard ICU ventilation with 30% O2. All patients receive guideline-based post-resuscitation care. Inclusion is conducted under a deferred consent model, with consent obtained from patients or legal representatives once clinically appropriate. The primary clinical efficacy outcome is serum neuron-specific enolase (NSE) concentration at 48 h, as a surrogate marker of neurological injury. Secondary outcomes include markers of myocardial and multiorgan injury, neuroimaging signs of brain injury, survival, and neurological recovery (Cerebral Performance Category, CPC) up to 6 months. Safety outcomes include the incidence, timing, and duration of O2 desaturation requiring discontinuation of Ar, and haemodynamic adverse events. Patients are followed up to 6 months, with outcome assessment at ICU/hospital discharge, 1-and 6-months post-CA. A centralized plasma and serum biobank will support future mechanistic analyses. Conclusion: CPAr trial is the first RCT to assess the efficacy and safety of Ar ventilation in humans following OHCA and may inform future neuroprotective strategies in post-resuscitation care. Trial registration: EudraCT-No.: 2018-003047-32; CTIS code: 2024-516864-27-00; ClinicalTrials.gov identifier: NCT05482945.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
